同步放化疗治疗中晚期宫颈癌的临床效果分析  

Clinical Analysis of Chemoradiotherapy for Patients with Metaphase or Advanced Cervical Cancer

作　　者：吴苏冬[1] 康静波[1] 聂青[1] 郭晓东[2] 

机构地区：[1]海军总医院,北京100048 [2]解放军第302医院,北京100039

出　　处：《现代生物医学进展》2013年第29期5704-5707,共4页Progress in Modern Biomedicine

基　　金：国家自然科学基金青年科学基金项目(81301239)

摘　　要：目的:子宫颈癌(Cervical Cancer)是女性生殖系统常见的恶性肿瘤,严重影响女性的身体健康及生活质量。本研究通过观察单纯放疗与同步放化疗治疗中晚期宫颈癌的临床效果,探讨治疗宫颈癌的最佳方式,为后续临床研究提供参考。方法:选取我院2008年1月-2009年6月收治的中晚期宫颈癌患者124例,随机分为同步放化疗组和单纯放疗组,每组62例。单纯放疗组采取腔内或腔外照射的方式进行放射治疗,而同步放化疗组在此基础上采用多烯紫杉醇+顺铂(DP)方案进行治疗。观察并比较两组患者的近期临床疗效、毒副反应发生率及随访情况。结果:同步放化疗组的治疗总有效率、毒副反应发生率均高于单纯放疗组,但患者经对症处理后均获得改善;同步放化疗组三年生存率高于单纯放疗组,差异均具有统计学意义(P<0.05)。结论:在中晚期宫颈癌的临床治疗中,对患者实施放射治疗的同时选择合理的药物及给药方案进行化疗具有明显的近期疗效,患者的毒副反应可耐受,且治疗后的生存率较高,值得临床推广应用。Objective： Cervical cancer is a common malignant tumor of female reproductive system which has the serious impact on their health and life quality. This study aims to discuss the best method of cervical cancer by observing the clinical efficacy of the radiotherapy and the chemoradiotherapy on the treatment of metaphase and advanced cervical cancer in order to provide a reference for subsequent researches. Methods： 124 cases with metaphase and advanced cervical cancer who were treated in our hospital from January 2008 to June 2009 were selected and randomly divided into the chemoradiotherapy group and the radiotherapy group with 62 patients in each one. The patients in the radiotherapy group were treated by the radiation of cavity or external chamber, while the patients in the chemoradiotherapy group were performed by the polyene paclitaxel combined with the cisplatin on the basis of radiotherapy. Then the clinical effects, the incidence of adverse reactions and the situation of follow-ups were observed and compared between two groups. Results： The total effective rate and the incidence of adverse reactions of patients in the chemoradiotherapy group were higher than those of the patients in the radiotherapy group, and the patients with adverse reactions got improvement by symptomatic treatments; The survival rate of three years in the chemoradiotherapy group was better than that of the patients in the radiotherapy group with statistically significant differences（P〈0.05）. Conclusions： It is suggested that the chemoradiotherapy should be well promoted to the clinical treatment for patients with the metaphase or advanced cervical cancer when applied with the reasonable medication and dosage regimen, because the clinical effects and the survival rate of patients were obviously higher, and the patients could tolerate the adverse reactions.

关 键 词：宫颈癌 放射治疗 同步放化疗 疗效分析 

分 类 号：R737.3[医药卫生—肿瘤]